Stocktoria
Compass Therapeutics, Inc. CMPX
Nasdaq · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2020-11-13
Compass Therapeutics, Inc. financials (annual)
Bars are annual figures from 2019 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2020 | FY2019 | FY2019 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $850,000 | $0 | — | — | — | — | — | — |
| R&D expense | $56.0M | $42.3M | $38.1M | — | — | $14.9M | — | $22.4M | — |
| Operating income | -$72.8M | -$56.6M | -$50.4M | -$41.7M | -$81.9M | -$27.8M | -$32,105 | -$34.1M | -$32,759 |
| Interest expense | — | — | — | $0 | $370,000 | $908,000 | $5,378 | $1.2M | $3,278 |
| Income tax | $0 | $0 | $0 | $0 | $0 | $32,000 | — | $91,000 | — |
| Net income | -$66.5M | -$49.4M | -$42.5M | -$39.2M | -$82.2M | -$29.5M | -$37,483 | -$34.7M | -$36,037 |
| Operating cash flow | -$49.1M | -$44.9M | -$40.6M | -$34.1M | -$19.7M | -$26.8M | -$32,106 | -$31.7M | -$32,759 |
| Free cash flow | -$49.2M | -$44.9M | -$40.6M | -$34.3M | -$21.2M | -$26.9M | — | -$32.2M | — |
| Cash & equivalents | $30.6M | $43.5M | $24.2M | $34.9M | $144.5M | $47.1M | $3,745 | $25.3M | $4,866 |
| Total assets | $219.6M | $140.4M | $156.9M | $199.6M | $153.8M | $51.9M | $3,745 | $30.4M | $4,866 |
| Total liabilities | $22.8M | $15.2M | $8.3M | $18.0M | $13.7M | $12.0M | $111,817 | $19.1M | $75,455 |
| Shareholders' equity | $196.8M | $125.2M | $148.5M | $181.6M | $140.1M | $39.9M | -$124.8M | $11.3M | -$95.3M |
Growth · year-over-year
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2020 | FY2019 | FY2019 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | -100.0% | — | — | — | — | — | — | — | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.